Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells

Shin Ichiro Maehara, Shinji Tanaka, Mitsuo Shimada, Ken Shirabe, Yoshiro Saito, Kazuhiko Takahashi, Yoshihiko Maehara

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Gemcitabine is a new standard chemotherapeutic agent used in the treatment of pancreatic cancer, but the mechanisms of gemcitabine sensitivity are still controversial. In our study to determine a mechanism that regulates gemcitabine sensitivity, we carried out molecular analysis on the susceptibility of the pancreatic cancer cells. Using a gemcitabine-sensitive pancreatic cancer cell line KLM1, we established a resistant cell line KLM1-R exhibiting a 20-fold IC50-value (the concentration of gemcitabine causing 50% growth inhibition). Microarray analysis of genes showed specific expression of selenoprotein P, one of the anti-oxidants, in the KLM1-R cell line but not in the KLM1 cell line. Administration of seleno-protein P inhibited the gemcitabine-induced cytotoxicity in the pancreatic cell lines. The levels of intracellular reactive oxygen species (ROS) were increased in the KLM1 cells by gemcitabine, but selenoprotein P suppressed the gemcitabine-induced ROS levels. Furthermore interferon-γ suppressed the expression of selenoprotein P mRNA and increased intracellular ROS level, leading to the recovery of the gemcitabine sensitivity in KLM1-R. These results suggest a novel mechanism that selenoprotein P reduces the intracellular ROS levels, resulting in the insusceptibility to gemcitabine.

Original languageEnglish
Pages (from-to)184-189
Number of pages6
JournalInternational Journal of Cancer
Volume112
Issue number2
DOIs
Publication statusPublished - Nov 1 2004

Fingerprint

gemcitabine
Selenoprotein P
Pancreatic Neoplasms
Reactive Oxygen Species
Cell Line
Microarray Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Maehara, S. I., Tanaka, S., Shimada, M., Shirabe, K., Saito, Y., Takahashi, K., & Maehara, Y. (2004). Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. International Journal of Cancer, 112(2), 184-189. https://doi.org/10.1002/ijc.20304

Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. / Maehara, Shin Ichiro; Tanaka, Shinji; Shimada, Mitsuo; Shirabe, Ken; Saito, Yoshiro; Takahashi, Kazuhiko; Maehara, Yoshihiko.

In: International Journal of Cancer, Vol. 112, No. 2, 01.11.2004, p. 184-189.

Research output: Contribution to journalArticle

Maehara, SI, Tanaka, S, Shimada, M, Shirabe, K, Saito, Y, Takahashi, K & Maehara, Y 2004, 'Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells', International Journal of Cancer, vol. 112, no. 2, pp. 184-189. https://doi.org/10.1002/ijc.20304
Maehara, Shin Ichiro ; Tanaka, Shinji ; Shimada, Mitsuo ; Shirabe, Ken ; Saito, Yoshiro ; Takahashi, Kazuhiko ; Maehara, Yoshihiko. / Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. In: International Journal of Cancer. 2004 ; Vol. 112, No. 2. pp. 184-189.
@article{83c815cd931144f7b9818b7710796577,
title = "Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells",
abstract = "Gemcitabine is a new standard chemotherapeutic agent used in the treatment of pancreatic cancer, but the mechanisms of gemcitabine sensitivity are still controversial. In our study to determine a mechanism that regulates gemcitabine sensitivity, we carried out molecular analysis on the susceptibility of the pancreatic cancer cells. Using a gemcitabine-sensitive pancreatic cancer cell line KLM1, we established a resistant cell line KLM1-R exhibiting a 20-fold IC50-value (the concentration of gemcitabine causing 50{\%} growth inhibition). Microarray analysis of genes showed specific expression of selenoprotein P, one of the anti-oxidants, in the KLM1-R cell line but not in the KLM1 cell line. Administration of seleno-protein P inhibited the gemcitabine-induced cytotoxicity in the pancreatic cell lines. The levels of intracellular reactive oxygen species (ROS) were increased in the KLM1 cells by gemcitabine, but selenoprotein P suppressed the gemcitabine-induced ROS levels. Furthermore interferon-γ suppressed the expression of selenoprotein P mRNA and increased intracellular ROS level, leading to the recovery of the gemcitabine sensitivity in KLM1-R. These results suggest a novel mechanism that selenoprotein P reduces the intracellular ROS levels, resulting in the insusceptibility to gemcitabine.",
author = "Maehara, {Shin Ichiro} and Shinji Tanaka and Mitsuo Shimada and Ken Shirabe and Yoshiro Saito and Kazuhiko Takahashi and Yoshihiko Maehara",
year = "2004",
month = "11",
day = "1",
doi = "10.1002/ijc.20304",
language = "English",
volume = "112",
pages = "184--189",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells

AU - Maehara, Shin Ichiro

AU - Tanaka, Shinji

AU - Shimada, Mitsuo

AU - Shirabe, Ken

AU - Saito, Yoshiro

AU - Takahashi, Kazuhiko

AU - Maehara, Yoshihiko

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Gemcitabine is a new standard chemotherapeutic agent used in the treatment of pancreatic cancer, but the mechanisms of gemcitabine sensitivity are still controversial. In our study to determine a mechanism that regulates gemcitabine sensitivity, we carried out molecular analysis on the susceptibility of the pancreatic cancer cells. Using a gemcitabine-sensitive pancreatic cancer cell line KLM1, we established a resistant cell line KLM1-R exhibiting a 20-fold IC50-value (the concentration of gemcitabine causing 50% growth inhibition). Microarray analysis of genes showed specific expression of selenoprotein P, one of the anti-oxidants, in the KLM1-R cell line but not in the KLM1 cell line. Administration of seleno-protein P inhibited the gemcitabine-induced cytotoxicity in the pancreatic cell lines. The levels of intracellular reactive oxygen species (ROS) were increased in the KLM1 cells by gemcitabine, but selenoprotein P suppressed the gemcitabine-induced ROS levels. Furthermore interferon-γ suppressed the expression of selenoprotein P mRNA and increased intracellular ROS level, leading to the recovery of the gemcitabine sensitivity in KLM1-R. These results suggest a novel mechanism that selenoprotein P reduces the intracellular ROS levels, resulting in the insusceptibility to gemcitabine.

AB - Gemcitabine is a new standard chemotherapeutic agent used in the treatment of pancreatic cancer, but the mechanisms of gemcitabine sensitivity are still controversial. In our study to determine a mechanism that regulates gemcitabine sensitivity, we carried out molecular analysis on the susceptibility of the pancreatic cancer cells. Using a gemcitabine-sensitive pancreatic cancer cell line KLM1, we established a resistant cell line KLM1-R exhibiting a 20-fold IC50-value (the concentration of gemcitabine causing 50% growth inhibition). Microarray analysis of genes showed specific expression of selenoprotein P, one of the anti-oxidants, in the KLM1-R cell line but not in the KLM1 cell line. Administration of seleno-protein P inhibited the gemcitabine-induced cytotoxicity in the pancreatic cell lines. The levels of intracellular reactive oxygen species (ROS) were increased in the KLM1 cells by gemcitabine, but selenoprotein P suppressed the gemcitabine-induced ROS levels. Furthermore interferon-γ suppressed the expression of selenoprotein P mRNA and increased intracellular ROS level, leading to the recovery of the gemcitabine sensitivity in KLM1-R. These results suggest a novel mechanism that selenoprotein P reduces the intracellular ROS levels, resulting in the insusceptibility to gemcitabine.

UR - http://www.scopus.com/inward/record.url?scp=4544267592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544267592&partnerID=8YFLogxK

U2 - 10.1002/ijc.20304

DO - 10.1002/ijc.20304

M3 - Article

C2 - 15352029

AN - SCOPUS:4544267592

VL - 112

SP - 184

EP - 189

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -